Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

97 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Completed

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

NCT01051817

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +7 more
Locations
  • Novartis Investigative Site Hradec Králové, Czech Republic, Czechia
  • Novartis Investigative Site Ostrava, Czechia
  • Novartis Investigative Site Ostrava-Moravska Ostrava, Czechia
  • Novartis Investigative Site Prague, Czechia
View all 16 locations
View Trial Details
Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Cullman, Alabama, United States
  • Research Site Huntsville, Alabama, United States
  • Research Site Phoenix, Arizona, United States
View all 195 locations
View Trial Details
Completed

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

NCT00420212

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site San Francisco, California, United States
  • Research Site New Haven, Connecticut, United States
View all 159 locations
View Trial Details
Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +12 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Scottsdale, Arizona, United States
  • Research Site Berkeley, California, United States
  • Research Site Centennial, Colorado, United States
View Trial Details
Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT02142205

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Belgorod, Russia
  • Research Site Kaluga, Russia
  • Research Site Kazan', Russia
  • Research Site Krasnodar, Russia
View Trial Details

Related conditions